|
|
- 2016
托珠单抗与依那西普治疗类风湿关节炎疗效观察
|
Abstract:
摘要 目的回顾性比较托珠单抗与依那西普在治疗类风湿关节炎患者的疗效差异性.方法:收集给予托珠单抗或者依那西普联合改善病情抗风湿药(DMARDs)治疗的重度活动类风湿关节炎住院患者30例, 分别记录两组患者治疗前、治疗后第4周、第12 周时患者临床症状及实验室指标的变化情况,并进行对比分析.结果:两组患者治疗前、治疗后第4周、第12 周时临床症状及实验室指标均有一定改善,且随治疗时间的延长,各项实验指标呈进行性下降趋势.治疗4周后托珠单抗组类风湿关节炎疾病活动度评分(DAS28评分)显著低于依那西普组,有统计学差异(2.5 vs 3.5,P=0.03);治疗12周后托珠单抗组类风湿因子水平显著低于依那西普组,有统计学差异(45.3 vs 105.8,P=0.04);治疗4周及12周后两组达到美国风湿病学会20(ACR20)标准、美国风湿病学会50(ACR50)标准的比例相当,差异无统计学意义.结论:托珠单抗治疗RA疗效确切,更快降低DAS 28水平,更显著降低类风湿因子水平.
| [1] | OHTA S, HARIGAI M,TANAKA M,et al.Tumor necrosis factor-alpha (TNF-alpha) converting enzyme cont ributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis[J]. Rheumatol,2001,28(8):1756-1763. |
| [2] | DAYER J M,CHOY E.Therapeutic targets in rheumatoid arthritis:the interleukin-6 recepto[J].Rheumatology(Oxford),2010,49(1):15-24. |
| [3] | TAGA T,KISHIMOTO T.Gp130 and the interleukin-6 family of cytokines[J].Annu Rev Immunol,1997,15(2):797-819. |
| [4] | YAZICI Y,CURTIS J R,INCE A,et al.Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study[J]. Ann Rheum Dis,2012,71(2):198-205 |
| [5] | 史 群, 赵 岩, 鲍春德, 等. 托珠单抗联合改善病情抗风湿药治疗类风湿关节炎的多中心、随机、双盲、安慰剂对照临床研究[J]. 中华内科杂志, 2013, 52(4): 323-329. |
| [6] | GENOVESE M C,MCKAY J D,NASONOV E L,et al.Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study[J].Arthritis Rheum,2008,58(10):2968-2980. |
| [7] | HASHIMOTO J,GARNERO P,VAN DER HEIJDE D,et al.Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study[J].Mod Rheumatol,2011,21(1):10-15. |
| [8] | DOUGADOS M,KISSEL K,SHEERAN T,et al.Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)[J].Ann Rheum Dis,2013,72(1):43-50. |
| [9] | JONES G,SEBBA A,LOWENSTEIN M B,et al.Comparison of tocilizumab monotherapy versus methotrexate monotherapyin patients with moderate to severe rheumatoid arthritis: the AMBITION study[J].Ann Rheum Dis,2010,69(1):88-96. |
| [10] | HIRABARA S,TAKAHASHI N,FUKAYA N,et al.Clinical efficacy of abatacept, tocilizumab,and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies[J].Clin Rheumatol,2014,33(9):1247-1254. |
| [11] | VIVIAN P,BYKERK,ANDREW J,et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice[J]. Clin Rheumatol,2015,34(3):563-571. |
| [12] | WRIGHT H L,CROSS A L,EDWARDS S W,et al.Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo[J].Rheumatology,2014,53(7):1321-1331. |
| [13] | NAKASHIMA Y,KONDO M,HARADA H,et al.Clinical evaluation of tocilizumab for patients with activerheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate[J].Mod Rheumatol,2010,20(4):343-352. |
| [14] | WEINBALTT M E,KREMER J,CUSH J,et al.Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study[J].Arthritis Care Res (Hoboken),2013,65(3):362-371. |
| [15] | BACKHAUS M,KAUFMANN J,RICHRER C,et al.Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis:a retrospective analysis of 1603 patients managed in routiyne clinica practice[J].Clin Rheumatol,2015,34(4): 673-681. |
| [16] | ABDEL MEGUID M H,HAMAD Y H,SWILAM R S,et al.Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage[J]. Rheumatol Int,2013,33(3):697-703. |
| [17] | 艾脉兴,马 丽,赵孟君,等.依那西普治疗活动性类风湿关节炎的安全性和有效性[J].中国新药杂志,2007,16(15):1208-1211. |
